Faes Farma


PHARMAS WAKE UP?

10/06/21 -"By gaining 9% over last week, Roche (Add, Switzerland), the largest European pharma by market cap, set the sector on fire. This was overdue as shown by the following one-year performance chart. ..."

Pages
43
Language
English
Published on
10/06/21
You may also be interested by these reports :
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...

25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...

25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...

24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO